Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5049)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Jul 24, 2021 (publication date) through Apr 26, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Imyanitov E, Sokolenko A. Mechanisms of acquired resistance of BRCA1/2-driven tumors to platinum compounds and PARP inhibitors. World J Clin Oncol 2021; 12(7): 544-556 [PMID: 34367927 DOI: 10.5306/wjco.v12.i7.544] |
|---|---|
| URL: | https://www.wjgnet.com/2218-4333/full/v12/i7/544.htm |
| Number | Citing Articles |
| 1 |
Tu Le, Pilar Soto Rojas, Mary Fakunle, Franklin W. Huang. Racial disparity in the genomics of precision oncology of prostate cancer. Cancer Reports 2023; 6(S1) doi: 10.1002/cnr2.1867
|
| 2 |
Cecilia Ayala-Zambrano, Mariana Yuste, Sara Frias, Benilde Garcia-de-Teresa, Luis Mendoza, Eugenio Azpeitia, Alfredo Rodríguez, Leda Torres. A Boolean network model of the double-strand break repair pathway choice. Journal of Theoretical Biology 2023; 573: 111608 doi: 10.1016/j.jtbi.2023.111608
|
| 3 |
Anne Vogel, Anna Haupts, Michael Kloth, Wilfried Roth, Nils Hartmann. A novel targeted NGS panel identifies numerous homologous recombination deficiency (HRD)-associated gene mutations in addition to known BRCA mutations. Diagnostic Pathology 2024; 19(1) doi: 10.1186/s13000-023-01431-8
|
| 4 |
Evgeny N. Imyanitov. Cytotoxic and targeted therapy for BRCA1/2-driven cancers. Hereditary Cancer in Clinical Practice 2021; 19(1) doi: 10.1186/s13053-021-00193-y
|
| 5 |
Evgeny Imyanitov, Anna Sokolenko. Integrative Genomic Tests in Clinical Oncology. International Journal of Molecular Sciences 2022; 23(21): 13129 doi: 10.3390/ijms232113129
|
| 6 |
Evgeny N. Imyanitov, Aglaya G. Iyevleva. Molecular tests for prediction of tumor sensitivity to cytotoxic drugs. Cancer Letters 2022; 526: 41 doi: 10.1016/j.canlet.2021.11.021
|
| 7 |
Muhammad Muzamil Khan, Satya Siva Kishan Yalamarty, Bharat Ashok Rajmalani, Nina Filipczak, Vladimir P. Torchilin. Recent strategies to overcome breast cancer resistance. Critical Reviews in Oncology/Hematology 2024; 197: 104351 doi: 10.1016/j.critrevonc.2024.104351
|
| 8 |
Rafael Vázquez-Romo, Oliver Millan-Catalan, Erika Ruíz-García, Antonio D. Martínez-Gutiérrez, Alberto Alvarado-Miranda, Alma D. Campos-Parra, César López-Camarillo, Nadia Jacobo-Herrera, Eduardo López-Urrutia, Mariano Guardado-Estrada, David Cantú de León, Carlos Pérez-Plasencia. Pathogenic variant profile in DNA damage response genes correlates with metastatic breast cancer progression-free survival in a Mexican-mestizo population. Frontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1146008
|
| 9 |
Svetlana N. Aleksakhina, Alexander O. Ivantsov, Evgeny N. Imyanitov. Agnostic Administration of Targeted Anticancer Drugs: Looking for a Balance between Hype and Caution. International Journal of Molecular Sciences 2024; 25(7): 4094 doi: 10.3390/ijms25074094
|